Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,847
datasets available to search
ShareScore release 0.9.0
Dataset results
1,847 results for “Psoriasis”
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT01163253. IPD Sharing: YES. Countries: 36. Publications: 4.
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
ClinicalTrials.gov study NCT00988637. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT03536884. IPD Sharing: YES. Countries: 11. Publications: 11.
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
ClinicalTrials.gov study NCT03942042. IPD Sharing: YES. Countries: 1. Publications: 1.
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
ClinicalTrials.gov study NCT01947491. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT01241591. IPD Sharing: Not stated. Countries: 26. Publications: 3.
Safety and Efficacy of Secukinumab in Mild Psoriasis
ClinicalTrials.gov study NCT03131570. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
ClinicalTrials.gov study NCT04102007. IPD Sharing: YES. Countries: 8. Publications: 1.
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
ClinicalTrials.gov study NCT00773734. IPD Sharing: Not stated. Countries: 2. Publications: 8.
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT01186744. IPD Sharing: Not stated. Countries: 12. Publications: 2.
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT01988103. IPD Sharing: YES. Countries: 1. Publications: 3.
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
ClinicalTrials.gov study NCT04655313. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
ClinicalTrials.gov study NCT03090100. IPD Sharing: Not stated. Countries: 9. Publications: 4.
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT02576678. IPD Sharing: YES. Countries: 4. Publications: 1.
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
ClinicalTrials.gov study NCT01624233. IPD Sharing: YES. Countries: 1. Publications: 2.
Vascular Inflammation in Psoriasis - Apremilast
ClinicalTrials.gov study NCT03082729. IPD Sharing: NO. Countries: 1. Publications: 1.
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
ClinicalTrials.gov study NCT05969223. IPD Sharing: YES. Countries: 1. Publications: 1.
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT02070965. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov study NCT03478787. IPD Sharing: YES. Countries: 9. Publications: 1.
Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis
ClinicalTrials.gov study NCT02107482. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.